Veloxis Pharmaceuticalsincis A Specialty Pharmaceutical Company Focused On Improving The Lives Of Transplant Patientsas A Subsidiary Of Asahi Kasei Corporationveloxis Is Headquartered In Carynorth Carolinathe Company Is Dedicated To The Researchdevelopmentmanufactureand Sale Of Pharmaceuticals Specifically For Organ Transplantation The Flagship Product Of Veloxis Is Envarsus Xran Extended Release Tablet Of Tacrolimus Used To Prevent Organ Rejection In Kidney Transplant Patientsthis Medication Features The Proprietary Meltdose Technologywhich Enhances Drug Absorption And Bioavailabilityveloxis Aims To Support Transplant Healthcare Providers And Patients By Developing Innovative Therapies And Programs That Address Challenges Throughout The Transplant Journey
